PLoS ONE (Jan 2023)

A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA

  • Andhika Rachman,
  • Anggraini Iriani,
  • Lugyanti Sukrisman,
  • Wulyo Rajabto,
  • Nadia Ayu Mulansari,
  • Anna Mira Lubis,
  • Rahmat Cahyanur,
  • Findy Prasetyawati,
  • Dimas Priantono,
  • Bayu Bijaksana Rumondor,
  • Rachelle Betsy,
  • Samuel Juanputra

Journal volume & issue
Vol. 18, no. 3

Abstract

Read online

Background Cancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines, either with BNT162b2, mRNA-1273, AZD1222/ChAdOx1nCoV-19, or Coronavac/BBIBP-CorV vaccines. Method A cross-sectional study was conducted among subjects with either solid or hematological cancers who had received two doses of either mRNA or non-mRNA vaccines within 6 months. The levels of anti-SARS-CoV-2 S-RBD IgG and NAb were analyzed using the Mindray Immunoassay Analyzer CL-900i. Statistical analysis was conducted using mean comparison and regression analysis. Result The mRNA-1273 vaccine had the highest median levels of S-RBD IgG and NAb, followed by BNT162b, ChAdOx1nCoV-19, and BBIBP-CorV/Coronavac. The levels of S-RBD IgG and NAb in subjects vaccinated with mRNA vaccines were significantly higher than those of non-mRNA vaccines when grouped based on their characteristics, including age, type of cancer, chemotherapy regimen, and comorbidity (pConclusions Generally, mRNA vaccines produced significantly higher anti-SARS-CoV-2 S-RBD IgG and NAb levels than non-mRNA vaccines in cancer subjects.